KRRO

Korro Bio Inc

12.05

Oct 22 • 3:59 PM ET +2.76 (29.71%)

12.04

Aftermarket • 7:57 PM ET -0.01 (-0.08%)

Healthcare Biotechnology USA Micro NASD

Today, 7:05 AMKorro Bio reports preclinical KRRO-111 data with up to 96% SERPINA1 mRNA editing and 95% hepatic Z-AAT reduction in AATD

Peers: PRQR WVE ADRX SLN ARWR PRME BEAM STOK IONS ALNY

| Held by: VTI IWM VXF IWN VTWO LFSC IWC VHT AVSC DFAS

Scroll to Statements

Index	RUT
Market Cap	177.44M
Enterprise Value	104.61M
Income	-106.64M
Sales	2.38M
Book/sh	7.02
Cash/sh	7.81
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	58
IPO	Oct 03, 2019

P/E	-
Forward P/E	-
PEG	-
P/S	74.56
P/B	1.72
P/C	1.54
P/FCF	-
EV/EBITDA	-
EV/Sales	43.95
Quick Ratio	9.55
Current Ratio	9.55
Debt/Eq	0.41
LT Debt/Eq	0.38
Option/Short	Yes / Yes

EPS (ttm)	-10.01
EPS next Y	-4.88
EPS next Q	-1.26
EPS this Y	57.40%
EPS next Y	8.16%
EPS next 5Y	30.71%
EPS past 3/5Y	62.00% 21.21%
Sales past 3/5Y	- -29.61%
EPS Y/Y TTM	-2.62%
Sales Y/Y TTM	-62.08%
EPS Q/Q	60.88%
Sales Q/Q	-100.00%
Earnings	Aug 06 BMO
EPS/Sales Surpr.	20.03% -100.00%

Insider Own	30.28%
Insider Trans	-5.44%
Inst Own	67.99%
Inst Trans	14.70%
ROA	-62.03%
ROE	-97.69%
ROIC	-74.84%
Gross Margin	-10.37%
Oper. Margin	-3176.57%
Profit Margin	-4477.08%
SMA20	24.61%
SMA50	5.65%
SMA200	2.10%
Trades

Shs Outstand	14.71M
Shs Float	10.27M
Short Float	16.31%
Short Ratio	11.18
Short Interest	1.68M
52W High	42.93 -71.93%
52W Low	5.20 131.53%
Volatility	13.01% 8.72%
ATR (14)	0.98
RSI (14)	62.26
Beta	3.30
Rel Volume	3.18
Avg Volume	149.89K
Volume	476,554

Perf Week	29.43%
Perf Month	22.58%
Perf Quarter	13.25%
Perf Half Y	-11.36%
Perf YTD	50.44%
Perf Year	-70.33%
Perf 3Y	-3.68%
Perf 5Y	-96.42%
Perf 10Y	-
Recom	1.25
Target Price	20.00
Prev Close	9.29
Price	12.05
Change %	29.71%

Date	Action	Analyst	Rating Change	Price Target Change
May-18-26	Initiated	Citigroup	Buy	$21
Mar-13-26	Upgrade	Raymond James	Mkt Perform → Outperform	$23
Feb-17-26	Upgrade	William Blair	Mkt Perform → Outperform
Jan-29-26	Upgrade	Piper Sandler	Neutral → Overweight	$30
Jan-29-26	Upgrade	H.C. Wainwright	Neutral → Buy	$20
Jan-29-26	Upgrade	Chardan Capital Markets	Neutral → Buy	$15
Jan-28-26	Upgrade	Oppenheimer	Perform → Outperform	$22
Jan-28-26	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$21
Nov-13-25	Downgrade	William Blair	Outperform → Mkt Perform
Nov-13-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$8
Nov-13-25	Downgrade	Raymond James	Strong Buy → Mkt Perform
Nov-13-25	Downgrade	Piper Sandler	Overweight → Neutral	$11
Nov-13-25	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-13-25	Downgrade	Chardan Capital Markets	Buy → Neutral	$7
Nov-13-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Apr-29-25	Initiated	Cantor Fitzgerald	Overweight	$74
Apr-16-25	Initiated	Chardan Capital Markets	Buy	$25
Jan-10-25	Initiated	Oppenheimer	Outperform	$155
Oct-21-24	Initiated	Raymond James	Strong Buy	$153
Aug-14-24	Initiated	William Blair	Outperform	$180

Show Previous Ratings

Today 07:00AM	Korro Reports Best-in-Class Preclinical Data for KRRO-111 Demonstrating Potential to Benefit Lung and Liver Manifestations of Alpha-1 Antitrypsin Deficiency (GlobeNewswire) +29.71%
Oct-16-26 04:05PM	Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.81%
Oct-05-26 04:05PM	Korro Announces First Cohort Dosed in Phase 1/2 Clinical Trial (ANCHOR) for KRRO-121 (GlobeNewswire)
Sep-11-26 04:05PM	Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.74%
Aug-27-26 07:00AM	Korro to Participate in Upcoming Investor Conferences (GlobeNewswire)
04:05PM	Loading…
Aug-14-26 04:05PM	Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-06-26 07:00AM	Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire) +5.39%
Jul-10-26 04:05PM	Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.28%
May-27-26 07:00AM	Korro to Present at the 2026 Jefferies Global Healthcare Conference (GlobeNewswire) +11.60%
May-19-26 07:00AM	Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire) -8.22%
May-15-26 04:05PM	Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.12%
May-07-26 07:00AM	Korro Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
May-05-26 04:05PM	Korro to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.96%
Apr-16-26 07:30AM	Korro Announces Oral and Poster Presentations at Upcoming Scientific Conferences (GlobeNewswire)
Apr-10-26 04:05PM	Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.97%
04:05PM	Loading…
Mar-12-26 04:05PM	Korro Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +11.30%
Mar-10-26 06:09AM	United Therapeutics (UTHR) Surges 10.7%: Is This an Indication of Further Gains? (Zacks) -6.67%
Mar-09-26 07:30AM	Korro Announces Oversubscribed $85 Million Private Placement (GlobeNewswire) +10.02%
Feb-26-26 12:15PM	Collegium Pharmaceutical (COLL) Q4 Earnings and Revenues Miss Estimates (Zacks)
Feb-25-26 04:05PM	Korro to Present at the TD Cowen 46th Annual Health Care Conference (GlobeNewswire)
Feb-02-26 09:53AM	H.C. Wainwright Flag KRRO-121 as Independent Value Driver for Korro Bio, Inc. (KRRO) (Insider Monkey)
Jan-30-26 07:35AM	Strength Seen in Korro Bio, Inc. (KRRO): Can Its 13.9% Jump Turn into More Strength? (Zacks)
03:08AM	Korro Bio Analyst Day: KRRO-121 RNA-Editing Candidate Targets Ammonia Control in UCD and HE (MarketBeat)
Jan-29-26 09:35AM	First Solar downgraded, Fortinet upgraded: Wall Street's top analyst calls (The Fly) +13.86%
Jan-20-26 08:00AM	Korro to Host Virtual Analyst Day on January 27, 2026 (GlobeNewswire)
Jan-08-26 08:00AM	Korro to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +7.77%
Nov-13-25 09:45AM	Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls (The Fly) -79.31%
09:37AM	Korro Bio Plummets To A Record Low On A Big Setback In RNA-Editing (Investor's Business Daily)
Nov-12-25 05:59PM	This biotech is halting its work with Novo Nordisk and laying off more people (MarketWatch)
05:40PM	Korro Bio, Inc. (KRRO) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Loading…
04:05PM	Korro Reports Third Quarter Financial Results, Provides Updates on KRRO-110 in Alpha-1 Antitrypsin Deficiency and Additional Pipeline Programs (GlobeNewswire)
Sep-02-25 04:30PM	Korro to Participate in Upcoming Investor and Scientific Conferences (GlobeNewswire) +17.25%
Aug-12-25 07:00AM	Korro Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire) +6.25%
Jul-21-25 08:00AM	Korro Receives European Medicines Agency Orphan Drug Designation for KRRO-110 (GlobeNewswire)
May-14-25 04:05PM	Korro to Participate in Upcoming Investor Conferences (GlobeNewswire) -9.26%
May-09-25 10:31AM	Korro Bio price target lowered to $53 from $130 at H.C. Wainwright (TipRanks)
May-07-25 04:30PM	Korro Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire) -5.85% +10.55%
Apr-01-25 07:30AM	Korro Appoints Biotech Industry Veteran, Loic Vincent, Ph.D., as Chief Scientific Officer (GlobeNewswire) -8.39%
07:30AM	Korro Appoints Biotech Industry Veteran, Lo c Vincent, Ph.D., as Chief Scientific Officer (GlobeNewswire)
Mar-28-25 06:18PM	Korro Bio: Promising Early Stage RNA Editing Company (Seeking Alpha) -5.11%
Mar-18-25 07:00AM	Korro Reports Full Year 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-17-25 07:26AM	FDA grants orphan drug status for Korro Bio's AATD therapy (Pharmaceutical Business Review)
Mar-14-25 08:00AM	KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency (GlobeNewswire)
Feb-26-25 08:00AM	Korro to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Jan-13-25 08:00AM	Korro Bio Announces Dosing of First Participants in REWRITE Phase 1/2a Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency and Provides Pipeline Update (GlobeNewswire) +8.20%
Jan-07-25 08:00AM	Korro to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -7.23%
Dec-10-24 08:00AM	CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors (GlobeNewswire)
Nov-21-24 04:01PM	Korro to Participate in Upcoming Investor Conferences (GlobeNewswire) +7.70%
07:30AM	Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency (GlobeNewswire)
Nov-14-24 08:00AM	Korro to Present at the Jefferies London Healthcare Conference (GlobeNewswire) -9.65%
Nov-12-24 04:05PM	Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -11.37% -15.55%
Nov-04-24 07:25AM	Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board (GlobeNewswire)
Oct-21-24 04:15PM	Korro Bio Is Lagging Wave Life Sciences In RNA Editing. Why It Could Ultimately Lead The Space. (Investor's Business Daily) -5.22% -7.70%
Oct-16-24 04:20PM	Wave Life Sciences Just Edited RNA. Why Its Key Rival, Korro Bio, Skyrocketed. (Investor's Business Daily) +93.66%
Sep-30-24 08:00AM	Korro Announces Oral and Poster Presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society (GlobeNewswire)
Sep-16-24 08:00AM	Korro Bio Announces Collaboration with Novo Nordisk to Develop Two Therapeutic Candidates (GlobeNewswire)
Sep-10-24 08:00AM	Korro to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-28-24 08:00AM	Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors (GlobeNewswire)
Aug-27-24 08:00AM	Korro to Participate in Upcoming September Investor and Scientific Conferences (GlobeNewswire)
Aug-13-24 04:01PM	Korro Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) +9.21%
Jul-01-24 08:00AM	Korro Joins the Russell 2000 , Russell 3000 , and Russell Microcap Indexes (GlobeNewswire)
Jun-25-24 12:53PM	KRRO Stock Earnings: Korro Bio Beats EPS for Q4 2023 (InvestorPlace)
May-30-24 04:01PM	Korro to Participate in Upcoming June Investor and Scientific Conferences (GlobeNewswire)
May-20-24 02:30PM	Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International Conference (GlobeNewswire)
May-14-24 10:55PM	KRRO Stock Earnings: Korro Bio Beats EPS for Q1 2024 (InvestorPlace) +5.43%
04:01PM	Korro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical Officer (GlobeNewswire)
Apr-18-24 08:30AM	Korro Announces $70 Million Private Placement (GlobeNewswire)
Apr-01-24 04:01PM	Korro to Participate in Upcoming Investor Conferences (GlobeNewswire) -7.90%
Mar-26-24 04:01PM	Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress (GlobeNewswire) +18.43%
Feb-27-24 09:55AM	Wall Street Analysts Believe Korro Bio, Inc. (KRRO) Could Rally 86.94%: Here's is How to Trade (Zacks) -6.08%
08:00AM	Korro to Present at the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Feb-09-24 09:55AM	Does Korro Bio, Inc. (KRRO) Have the Potential to Rally 59.66% as Wall Street Analysts Expect? (Zacks)
Jan-18-24 08:00AM	Korro Bio Highlights Data for its Lead Program in Alpha-1 Antitrypsin Deficiency (AATD) and Progress Across its RNA Editing Portfolio (GlobeNewswire) -5.98%
Jan-04-24 08:00AM	Korro to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-07-23 08:00AM	Korro Announces Selection of its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire) -14.67%
Nov-28-23 08:00AM	Korro Bio Appoints Dr. Rachel Meyers to Board of Directors (GlobeNewswire) +6.45%
Nov-03-23 03:31PM	UPDATE: Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million (GlobeNewswire) +5.94%
12:19PM	Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million (GlobeNewswire)
Aug-10-23 04:01PM	Frequency Therapeutics Provides Business Updates and Second Quarter 2023 Financial Results (Business Wire)
Jul-17-23 11:59AM	Frequency (FREQ) Up 77% on Merger Deal With Korro Bio (Zacks) -12.66%
Jul-14-23 11:22AM	Why Are Frequency Therapeutics Shares Surging Today (Benzinga) +77.47%
06:30AM	Korro Bio and Frequency Therapeutics Announce Merger Agreement (Business Wire)
May-12-23 04:01PM	Frequency Therapeutics Provides Business Updates and First Quarter 2023 Financial Results (Business Wire) -5.17%
Mar-10-23 07:30AM	Frequency Therapeutics Provides Business Updates and Fourth Quarter and Full Year 2022 Financial Results (Business Wire)
Feb-27-23 07:30AM	Frequency Therapeutics to Participate at Upcoming March Investor Conferences (Business Wire) +5.40%
Feb-13-23 01:55PM	Hearing loss startup to cut more than half of staff in wake of trial failure (American City Business Journals) -80.54%
11:17AM	Frequency Therapeutics' Lead Hearing Loss Program Flunks, Shifts Focus To Multiple Sclerosis, Shares Plunge (Benzinga)
08:05AM	Frequency Therapeutics Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss (Business Wire)
Dec-19-22 07:30AM	Frequency Therapeutics Announces Formation of Clinical Advisory Board for Remyelination in Multiple Sclerosis Program (Business Wire)
Dec-15-22 07:30AM	Frequency Therapeutics Announces First Patient Dosed in Phase 1b Study of FX-345, the Companys Second Therapeutic Candidate for Sensorineural Hearing Loss (Business Wire)
Nov-17-22 07:30AM	Frequency Therapeutics to Host Virtual Investor Event, Highlighting Hearing Restoration Candidate FX-322 in Advance of Q1 Clinical Results (Business Wire) -10.05%
Nov-08-22 04:05PM	Frequency Therapeutics Provides Business Updates and Third Quarter 2022 Financial Results (Business Wire) -9.51%
Oct-12-22 07:30AM	Frequency Therapeutics Completes Enrollment of Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss (Business Wire) +7.47%
Aug-30-22 07:30AM	Frequency Therapeutics to Participate in September Investor and Medical Conferences (Business Wire)
Aug-09-22 04:05PM	Frequency Therapeutics Provides Business Updates and Second Quarter 2022 Financial Results (Business Wire) -11.11% +9.00%
Jun-24-22 09:03AM	Frequency Therapeutics (NASDAQ:FREQ) one-year losses have grown faster than shareholder returns have fallen, but the stock jumps 41% this past week (Simply Wall St.) -7.59%
May-25-22 12:00PM	Frequency Therapeutics, Inc. (FREQ) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
May-18-22 07:30AM	Frequency Therapeutics to Participate in 2022 H.C. Wainwright Global Investment Conference (Business Wire) -9.02%
May-04-22 04:30PM	Frequency Therapeutics Provides Business Updates and First Quarter 2022 Financial Results (Business Wire)
Apr-22-22 07:30AM	Frequency Therapeutics to Participate in B. Riley Securities Neuro & Ophthalmology Investor Conference (Business Wire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
FORMELA JEAN FRANCOIS	Director	Sep 14 '26	Sale	14.12	38,490	543,479	132,650	Sep 15 04:15 PM
FORMELA JEAN FRANCOIS	Director	Sep 11 '26	Sale	13.99	10,200	142,698	139,252	Sep 15 04:15 PM
Atlas Venture Fund XI, L.P.	Shareholder	Sep 14 '26	Proposed Sale	13.81	31,888	440,373		Sep 14 04:58 PM
Atlas Venture Opportunity Fund	Shareholder	Sep 14 '26	Proposed Sale	13.81	6,602	91,174		Sep 14 04:58 PM
Dolan Oliver	Senior Vice President, Finance	Sep 11 '26	Sale	13.72	5	69	16,241	Sep 14 04:05 PM
Atlas Venture Fund XI, L.P.	Shareholder	Sep 11 '26	Proposed Sale	13.06	8,450	110,357		Sep 11 05:10 PM
Atlas Venture Opportunity Fund	Shareholder	Sep 11 '26	Proposed Sale	13.06	1,750	22,855		Sep 11 05:09 PM
Dolan Oliver	Officer	Sep 11 '26	Proposed Sale	13.72	5	69		Sep 11 04:25 PM
Dolan Oliver	Senior Vice President, Finance	Sep 08 '26	Sale	13.51	7,347	99,286	16,252	Sep 10 04:05 PM
Dolan Oliver	Senior Vice President, Finance	Sep 09 '26	Sale	13.60	6	82	16,246	Sep 10 04:05 PM
Dolan Oliver	Officer	Sep 09 '26	Proposed Sale	13.60	6	82		Sep 09 04:21 PM
Dolan Oliver	Officer	Sep 08 '26	Proposed Sale	13.51	7,347	99,286		Sep 08 04:15 PM
FORMELA JEAN FRANCOIS	Director	Aug 26 '26	Sale	13.96	300	4,188	141,002	Aug 28 04:30 PM
Atlas Venture Fund XI, L.P.	Shareholder	Aug 26 '26	Proposed Sale	13.73	249	3,419		Aug 26 05:23 PM
Atlas Venture Opportunity Fund	Shareholder	Aug 26 '26	Proposed Sale	13.73	51	700		Aug 26 05:23 PM
FORMELA JEAN FRANCOIS	Director	Aug 19 '26	Sale	14.00	28,468	398,552	141,053	Aug 21 04:20 PM
Atlas Venture Fund XI, L.P.	Shareholder	Aug 19 '26	Proposed Sale	13.22	23,584	311,780		Aug 19 05:36 PM
Atlas Venture Opportunity Fund	Shareholder	Aug 19 '26	Proposed Sale	13.22	4,884	64,566		Aug 19 05:36 PM
FORMELA JEAN FRANCOIS	Director	Aug 11 '26	Sale	13.96	2,143	29,916	145,937	Aug 13 05:04 PM
Lynx1 Capital Management LP	10% Owner	Aug 06 '26	Buy	11.40	5,222	59,530	1,543,518	Aug 13 09:54 AM
Lynx1 Capital Management LP	10% Owner	Aug 10 '26	Buy	13.19	1,462	19,279	1,544,980	Aug 13 09:54 AM
Atlas Venture Opportunity Fund	Shareholder	Aug 11 '26	Proposed Sale	13.49	368	4,964		Aug 11 06:00 PM
Atlas Venture Fund XI, L.P.	Shareholder	Aug 11 '26	Proposed Sale	13.49	1,775	23,945		Aug 11 06:00 PM
Aiyar Ram	President and CEO	Aug 04 '26	Sale	10.84	5,802	62,917	69,046	Aug 05 04:05 PM
Aiyar Ram	Officer	Aug 04 '26	Proposed Sale	114.26	5,802	662,917		Aug 04 04:40 PM
FORMELA JEAN FRANCOIS	Director	Jul 02 '26	Sale	14.03	100,700	1,412,821	154,811	Jul 07 06:04 PM
FORMELA JEAN FRANCOIS	Director	Jul 06 '26	Sale	13.96	9,323	130,149	146,305	Jul 07 06:04 PM
Atlas Venture Fund XI, L.P.	Shareholder	Jul 06 '26	Proposed Sale	14.00	817	11,438		Jul 06 05:15 PM
Atlas Venture Opportunity Fund	Shareholder	Jul 06 '26	Proposed Sale	14.00	8,506	119,084		Jul 06 05:15 PM
Atlas Venture Opportunity Fund	Shareholder	Jul 02 '26	Proposed Sale	13.65	14,745	201,269		Jul 02 04:41 PM
Atlas Venture Fund XI, L.P.	Shareholder	Jul 02 '26	Proposed Sale	13.65	85,955	1,173,286		Jul 02 04:41 PM
FORMELA JEAN FRANCOIS	Director	Jun 23 '26	Sale	14.25	119,005	1,695,821	176,649	Jun 24 08:09 PM
FORMELA JEAN FRANCOIS	Director	Jun 24 '26	Sale	14.61	48,438	707,491	169,556	Jun 24 08:09 PM
FORMELA JEAN FRANCOIS	Director	Jun 22 '26	Sale	13.95	3,962	55,270	194,075	Jun 24 08:09 PM
Atlas Venture Fund XI, L.P.	Shareholder	Jun 24 '26	Proposed Sale	13.71	41,345	566,840		Jun 24 05:50 PM
Atlas Venture Opportunity Fund	Shareholder	Jun 24 '26	Proposed Sale	13.71	7,093	97,245		Jun 24 05:50 PM
Atlas Venture Opportunity Fund	Shareholder	Jun 23 '26	Proposed Sale	13.90	17,426	242,221		Jun 23 06:12 PM
Atlas Venture Fund XI, L.P.	Shareholder	Jun 23 '26	Proposed Sale	13.90	101,579	1,411,948		Jun 23 06:12 PM
Atlas Venture Fund XI, L.P.	Shareholder	Jun 22 '26	Proposed Sale	12.99	21,339	277,194		Jun 22 05:32 PM
Atlas Venture Opportunity Fund	Shareholder	Jun 22 '26	Proposed Sale	12.99	3,661	47,556		Jun 22 05:30 PM
Chappell Todd	Chief Operating Officer	Jun 16 '26	Sale	10.83	3,168	34,309	16,964	Jun 17 04:14 PM
Vincent Loic A	Chief Scientific Officer	Jun 16 '26	Sale	10.83	3,418	37,017	18,297	Jun 17 04:11 PM
Cerio Jeffrey	General Counsel	Jun 16 '26	Sale	10.83	6,609	71,575	35,293	Jun 17 04:08 PM
Dolan Oliver	Senior Vice President, Finance	Jun 16 '26	Sale	10.83	3,383	36,638	18,099	Jun 17 04:05 PM
Vincent Loic A	Officer	Jun 16 '26	Proposed Sale	10.83	3,418	37,017		Jun 16 04:48 PM
Cerio Jeffrey	Officer	Jun 16 '26	Proposed Sale	10.83	6,609	71,576		Jun 16 04:44 PM
Dolan Oliver	Officer	Jun 16 '26	Proposed Sale	10.83	3,383	36,638		Jun 16 04:44 PM
Chappell Todd	Officer	Jun 16 '26	Proposed Sale	10.83	3,168	34,310		Jun 16 04:42 PM
Aiyar Ram	President and CEO	May 29 '26	Sale	12.98	15,152	196,673	74,848	Jun 02 07:00 AM
FORMELA JEAN FRANCOIS	Director	May 28 '26	Sale	13.95	2,860	39,897	194,655	Jun 01 05:35 PM
Aiyar Ram	Officer	May 29 '26	Proposed Sale	12.98	15,152	196,676		May 29 03:09 PM
Lynx1 Capital Management LP	10% Owner	Mar 31 '26	Buy	10.60	520	5,512	1,538,296	Apr 02 12:00 PM
Yang Rick	10% Owner	Mar 10 '26	Buy	11.11	207,100	2,300,881	1,297,893	Mar 12 08:15 PM
SANDELL SCOTT D	10% Owner	Mar 10 '26	Buy	11.11	207,100	2,300,881	1,297,893	Mar 12 08:15 PM
New Enterprise Associates 17,	10% Owner	Mar 10 '26	Buy	11.11	207,100	2,300,881	1,297,893	Mar 12 08:15 PM
Chang Carmen	10% Owner	Mar 10 '26	Buy	11.11	207,100	2,300,881	1,297,893	Mar 12 08:15 PM
BASKETT FOREST	10% Owner	Mar 10 '26	Buy	11.11	207,100	2,300,881	1,297,893	Mar 12 08:15 PM
Mathers Edward T	10% Owner	Mar 10 '26	Buy	11.11	207,100	2,300,881	1,297,893	Mar 12 08:15 PM
Makhzoumi Mohamad	10% Owner	Mar 10 '26	Buy	11.11	207,100	2,300,881	1,297,893	Mar 12 08:15 PM
Walker Paul Edward	10% Owner	Mar 10 '26	Buy	11.11	207,100	2,300,881	1,297,893	Mar 12 08:15 PM
Florence Anthony A. Jr.	10% Owner	Mar 10 '26	Buy	11.11	207,100	2,300,881	1,297,893	Mar 12 08:15 PM

Korro Bio, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of a new class of genetic medicines based on editing RNA. The company was founded by Nessan Bermingham, Jean-Francois B. Formela, Joshua Rosenthal, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA.

Ph.D.Dr. Ram Aiyar MBA

MBADr. Jean-Francois Formela M.D.

Chief Scientific OfficerDr. Loic Vincent Ph.D.

Pharm.D.Dr. Jeffrey M. Cerio J.D.

Co-Founder & AdvisorDr. Andrew Fraley Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KRRO

Korro Bio Inc

Upgrade your Finviz experience